Lviv clinical bulletin 2018, 4(24): 8-13

Efficiency of L-arginine and L-carnitine in the Complex Treatment of Patients With Acute Myocardial Infarction and Comorbid Metabolic Syndrome

M. Shved, M. Pelo

I. Horbachevsky Ternopil State Medical University

Introduction. According to the results of numerous studies, synergistic effects of various components of the metabolic syndrome (MS) play a major role in the development of atherosclerosis, coronary artery disease and myocardial infarction (MI), due to the formation of numerous hemodynamic, neurohumoral, immuno-inflammatory, procoagulant reactions, leading to metabolic disorders in the cardiac muscle and vascular endothelial dysfunction. These pathogenetic factors of MI development, its complications and their progression are present in all patients with MI associated with this comorbid condition. However, modern specific treatment of endothelial dysfunction and energy supply of the myocardium is not included in the relevant protocols for the treatment of MI due to the lack of sufficient evidence.

Aim. Evaluation of the clinical efficiency of L-arginine and L-carnitine in the complex treatment of patients with acute MI and comorbid metabolic syndrome.

Materials and methods. 82 patients diagnosed with acute MI and MS were examined and were divided into 2 groups depending on the type of treatment program.

Patients were examined by the standard clinical and anamnestic examination, anthropometry with body mass index identification, determining the lipid panel parameters, myocardial necrosis biomarkers, electrophysiological state assessment of the myocardium according to ECG, Holter monitoring of ECG and blood pressure, transthoracic echocardiogram.

Results and discussion. The comparative analysis of the structural and functional parameters of the heart, according to echocardiographic data of 34 patients with MI who received standard protocol treatment with the corresponding parameters in 48 patients who had received additional treatment including L-arginine and L-carnitine, showed that the size of the left atrium was significantly lower in the examined test group (p = 0.02), and slight decrease of the aorta size, the thickness of the interventricular septum, the diastolic size of the left and right ventricles, which led to the significant increase of left ventricle ejection fraction by 9,1 % (p = 0.01). At the same time, this group less frequently had an acute heart failure (p = 0.03), acute aneurysm of the left ventricle (p = 0.04), thromboendocarditis (p = 0.03), epistenocardiac endocarditis (p = 0.03) and disorders of cardiac rhythm and conductivity (p = 0.03).

Conclusions. Patients with myocardial infarction and comorbid metabolic syndrome have significant disorders of the structural and functional state of the heart and its electrical instability, which is accompanied by the decreasing of myocardial contractile function, rhythm and conduction disorders, which cause the development of vascular endothelial dysfunction and violation of energy supply of cardiomyocytes. Complex treatment of patients with acute myocardial infarction and comorbid metabolic syndrome, including L-arginine and L-carnitine, can significantly increase the myocardial contractile function and ensure its electrical stability, which is accompanied by the significant frequency of decreasing life-threatening complications.


  1. Kovalenko V.M., Kornatsky V.M. Problems of health and life expectancy in modern conditions. Kornatsky V.M,. editor. Kyiv: D. Strazhesko Institute of Cardiology;2017. 298 p. (Ukrainian).
  2. Kovalenko VN, Talaeva TV, Kozliuk AS. Metabolic syndrome: mechanisms of development, importance as a factor of cardiovascular risk, principles of diagnosis and treatment. Ukrainian Cardiology Journal. 2013;5:80-87. (Ukrainian).
  3. Kostina V.M., Ziuzin O.V., Zinchenko T. Metabolic syndrome: methods of diagnosis and rehabilitation. Ecology [Internet]. 2011 [cited 2018 Mar. 2];152(140):76-78. Available from: (Ukrainian).
  4. Kravchun P. State of systolic and diastolic left ventricular function in patients with postinfarction cardiosclerosis and obesity. IEJ. 2014;6:37-40. (Ukrainian).
  5. Kryvenko VI, Fedorova OP, Pakhomova SP, Kolesnyk MYu, Nepriadkina IV, Kachan IS. The main syndromes, associated with metabolic disorders in practice of general practitioner. Zaporizhzhia: ZDMU; 2016:10-19. (Ukrainian).
  6. Martyniuk HV, Skoreiko NT, Skoreiko RS, Skoreiko SS. Metabolic syndrome – some features of pathogenesis and its effect on the development of arterial hypertension. Bukovina Medical Journal. 2016;20(2):85-87. (Ukrainian).
  7. Myshchenko N. The Effect of L-arginine Supplementation on Blood Pressure in Patients with Type 2 Diabetes: A Double-Blind Randomized Clinical Trial. Diabetology, Thyroidology, Metabolic disorders [Internet]. 2017 [cited 2018 12]; 2(38). Available from: (Ukrainian).
  8. Mitchenko OI, Korpachev VV, Bahrii AE, Zviahina TV, Koval SM, Kovalova OM et al. Methodological recommendations of the Working Group on metabolic syndrome, diabetes, pre-diabetes and cardiovascular diseases of the Ukrainian Association of Cardiologists and the Ukrainian Association of Endocrinologists. Kyiv; 2009. 10 p. (Ukrainian).
  9. Mitchenko OI, Lutai MI. Methodical recommendations of the Association of Cardiologists of Ukraine and the Ukrainian Society for Atherosclerosis on the diagnosis of the prevention and treatment of dyslipidemia. Kyiv; 2017. 28 p. (Ukrainian).
  10. Mitchenko OI. On behalf of the Working Group on Metabolic Syndrome, Prediabetes and Cardiovascular Diseases of the Ukrainian Association of Cardiologists and the Ukrainian Association of Endocrinologists. Ukrainian Medical Journal. 2007;2(58):4-13. (Ukrainian).
  11. Netiazhenko VZ. The patient high cardiovascular risk: how to improve the prognosis. Internal Medicine. 2008;5:145-167. (Ukrainian).
  12. Khobzei MK, Sirenko YuM, Stepanenko AV, Morozov AM, Amosova KM et al. Unified clinical protocol for emergency, primary, secondary and tertiary care “Acute coronary syndrome with elevation of segment ST”. Kyiv; 2014. 78 p. (Ukrainian).
  13. Khotina SH, Sokolov MYu, Parkhomenko OM, Lishchyshyna OM, Amosova KM et al. Unified clinical protocol of emergency, primary, secondary and tertiary medical care and medical rehabilitation “Acute coronary syndrome without elevation of the ST segment”. Kyiv; 201 67 p. (Ukrainian).
  14. Shved MI, Beniv MYa, Levytska LV, Tsuhlevych LV. Influence of the main risk factors on the course of myocardial infarction by the patients with overweight. Bulletin of Scientific Research. 2017;1(86):21-27. (Ukrainian).
  15. Di Nicolantonio J J. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proceedings. 2013; 88(6):544-51. 
  16. Orea-Tejeda A, Orozco-Gutierrez JJ, Castillo-Martinez L, Keirns-Davies C, Montano-Hernandez P, Vazquez-Diaz O et al. Influence of L-arginine and citrulline on vascular endothelial function in patients with heart failure with preserved left ventricular ejection fraction. Therapia [Internet]. 2012 [cited 2018 12];5(69):44-48. Available from:
  17. Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Molecular and Cellular Biochem. 1998;180(1,2):33-41.